- Home
- EHAB vs ERAS Comparison
EHAB vs ERAS Comparison
Compare EHAB & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHAB
- ERAS
- Stock Information
- Founded
- EHAB 2014
- ERAS 2018
- Country
- EHAB United States
- ERAS United States
- Employees
- EHAB N/A
- ERAS N/A
- Industry
- EHAB Hospital/Nursing Management
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- EHAB Health Care
- ERAS Health Care
- Exchange
- EHAB Nasdaq
- ERAS Nasdaq
- Market Cap
- EHAB 405.4M
- ERAS 432.6M
- IPO Year
- EHAB N/A
- ERAS 2021
- Fundamental
- Price
- EHAB $7.68
- ERAS $1.16
- Analyst Decision
- EHAB Hold
- ERAS Strong Buy
- Analyst Count
- EHAB 3
- ERAS 6
- Target Price
- EHAB $8.50
- ERAS $4.83
- AVG Volume (30 Days)
- EHAB 311.6K
- ERAS 2.3M
- Earning Date
- EHAB 05-07-2025
- ERAS 05-07-2025
- Dividend Yield
- EHAB N/A
- ERAS N/A
- EPS Growth
- EHAB N/A
- ERAS N/A
- EPS
- EHAB N/A
- ERAS N/A
- Revenue
- EHAB $1,034,800,000.00
- ERAS N/A
- Revenue This Year
- EHAB $5.33
- ERAS N/A
- Revenue Next Year
- EHAB $4.86
- ERAS N/A
- P/E Ratio
- EHAB N/A
- ERAS N/A
- Revenue Growth
- EHAB N/A
- ERAS N/A
- 52 Week Low
- EHAB $6.85
- ERAS $1.01
- 52 Week High
- EHAB $10.70
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- EHAB 34.58
- ERAS 41.47
- Support Level
- EHAB $7.56
- ERAS $1.01
- Resistance Level
- EHAB $7.91
- ERAS $1.29
- Average True Range (ATR)
- EHAB 0.35
- ERAS 0.17
- MACD
- EHAB -0.08
- ERAS 0.00
- Stochastic Oscillator
- EHAB 9.42
- ERAS 31.25
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing an advanced, life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.